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Hematopoietic stem cell transplant (HSCT) recipients are at high risk of contracting Clostridium difﬁcile
infection (CDI). We systematically searched the PubMed and EMBASE databases through March 2014 and
performed a random-effects meta-analysis to estimate the prevalence and trends of CDI over time. Among 48
eligible articles that included 12,025 patients at risk, we estimated that 7.9% (95% conﬁdence interval [CI],
6.5% to 9.5%) of HSCT patients are diagnosed with CDI during the peri-transplantation and late post-
transplantation periods, an estimation that is relatively consistent across studies (s2 ¼ .032). Prevalence of
CDI is signiﬁcantly higher among the 5120 allogeneic patients (9.3% [95% CI, 7.0% to 11.9%]), compared with
the 4665 autologous patients (5.2% [95% CI, 3.8% to 6.9%]) (P ¼ .02), and as many as 1 of 10 allogeneic
transplant recipients are expected to be diagnosed with CDI compared with 1 of 20 autologous
transplantation patients. However, this difference did not reach statistical signiﬁcance when stratiﬁed data
from the same centers were examined (P ¼ .11). Importantly, we found an increasing trend of CDI diagnosis
both worldwide (P ¼ .02) and across studies conducted in North America (P ¼ .03) over the last 34 years.
Notably, studies with a follow-up period that extended through the late post-transplantation period (after
day þ100) had a similar prevalence of CDI as those that followed patients only during the peri-
transplantation period (up to day þ100) (P ¼ .94). In summary, CDI is common in the hematopoietic trans-
plantation setting and the majority of infections occur in the peri-transplantation period. The prevalence is
almost 9-times higher than that reported among all hospital stays, with an increasing trend over time.
 2014 American Society for Blood and Marrow Transplantation.MATERIALS AND METHODSINTRODUCTION
Clostridium difﬁcile is the most common cause of acute
infectious diarrhea in the hospital setting [1]. Although the
prevalence of other health careeassociated infections seems
to decline [2], the prevalence of C. difﬁcile infection (CDI) has
increased and has only recently reached a plateau [3].
Overall, the prevalence [4], morbidity, mortality [5], and
medical care costs of CDI have reached historic highs [6], and
the Centers for Disease Control and Prevention has catego-
rized C. difﬁcile as 1 of the 3 pathogens that are considered
“urgent threats” [7].
Studies highlighting the signiﬁcant prevalence of CDI
among hematopoietic stem cell transplantation (HSCT) pa-
tients are increasingly published [8]. The susceptibility of
this patient population to CDI can be attributed to the
frequent and prolonged contact with the health care setting,
as well as to the prolonged exposure to antibiotics. Also, the
high degree of immunosuppression and graft-versus-host-
disease (GVHD) appear to be independent predisposing
factors among allogeneic transplant recipients, possibly by
disrupting the colonic mucosa [9]. To study the epidemi-
ology of CDI in the hematopoietic transplantation setting,
we performed a systematic review and meta-analysis of
published studies.edgments on page 1653.
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We searched PubMed (1967 to March 2014) and EMBASE (1963 to April
2014) medical databases to identify studies that reported the prevalence of
CDI among patients who receive hematopoietic stem cell transplantation.
The concise search term was ([stem cell] OR marrow OR chord OR auto-
logous OR allogeneic) AND transplant* AND (clostrid* OR difﬁcile OR infect*
OR diarrhea OR [clostridium difﬁcile] OR [pseudomembranous colitis]).
Potentially eligible articles by title and abstract reading were assessed in full
text. The search was supplemented by reviewing reference lists of the
eligible studies. We included in our analysis both published literature and
abstracts from conference proceedings. The meta-analysis follows the
Meta-analysis of Observational Studies in Epidemiology guidelines [10]
(Supplementary Table S1).
Selection Criteria
Studies were considered eligible if they reported the prevalence of CDI
among HSCT patients during their hospitalization after stem cell
transplantation. A restriction for English literature was imposed.
Outcomes of Interest
The primary outcome of interest was the prevalence of CDI among HSCT
patients. CDI was deﬁned as diarrhea combined with a positive stool test
result for the presence of toxigenic C. difﬁcile. Prevalence was calculated as
the proportion of patients diagnosed with CDI among patients “at risk,” ie,
HSCT recipients. A subgroup analysis was performed for geographical re-
gion, year of study conduction, autologous and allogeneic transplantation,
duration of follow-up, and study design.
The peri-transplantation period was deﬁned as the pretransplantation
period, pre-engraftment period (approximately 0 to 30 days after trans-
plantation), and postengraftment period (approximately 30 to 100 days
after transplantation), whereas the late post-transplantation period was
considered to be the period after day þ100 of transplantation. The sec-
ondary outcome of interestwas the recurrence rate of CDI in infected patients
(deﬁned as complete abatement of CDI symptoms while on appropriate
therapy, followed by subsequent reappearance of diarrhea and other
symptoms after treatment has been stopped).
Data Extraction
Two reviewers (I.M.Z. and P.D.Z.) independently evaluated studies that
were considered for inclusion in the meta-analysis. Relevant information
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summarized using a spreadsheet. Data from trials published in duplicate
were included only once, and the maximum of relevant information was
extracted. Consensus was reached if there were any discrepancies between
the reviewers. The following data were extracted: ﬁrst, we extracted the
characteristics of each study, including the study design (prospective versus
retrospective), the country of origin, and the study period. Second, infor-
mation on the patient population, including underlying diagnosis, number
of HSCT patients, source of stem cells, type of transplantation (autologous or
allogeneic), number of C. difﬁcileeinfected patients, number of BI/NAP1/027
strains, and severity of CDI, was extracted. The severity of CDI was assessed
using the CDI severity score, with low severity representing uncomplicated
inpatient management without need for imaging; medium severity, the
presence of colitis on imaging; and severe disease represented by evidence
of sepsis, intensive care unit admission, surgery for colitis, or death due to
colitis [11]. Finally, we extracted the information relevant to the follow-up,
including the duration of follow-up and the number of recurrent episodes.
To model the time trends of CDI among HSCT patients, an index year of each
eligible study was determined. For this purpose, we used the year that the
study was conducted and not the year of publication. If the study did not
provide stratiﬁed data per year, a midyear was calculated.
Quality Assessment
Two reviewers (I.M.Z. and P.D.Z.) independently assessed the method-
ological quality of eligible studies using the Newcastle-Ottawa Quality
Assessment Scale, which is a “star-based” rating-system [12]. According to
the scale, studies were evaluated in the context of the representativeness of
the exposed cohort, ascertainment of exposure, demonstration that the
outcome of interest was not present at the start of the study, assessment of
outcome, adequacy of follow-up time for outcomes to occur, and adequacy
of follow-up of cohorts. Each study could receive up to 6 stars, as the ﬁelds
“selection of the nonexposed cohort,” and “comparability between cohorts”
were not applicable for our meta-analysis. The study population was
considered representative of the exposed cohort if CDI were reported among
all available transplantation patients and not among a speciﬁc subpopula-
tion. The follow-up time was deemed adequate for outcomes to occur if it
were at least 100 days or if it included the whole period of hospitalization.
Studies that received at least 4 stars were deemed of adequate quality to
extract relevant data.
Data Analysis
The meta-analysis was performed using a random-effects model to es-
timate the pooled (combined) prevalence and the 95% conﬁdence intervals
(CI), using Der-Simonian and Laird weights [13]. To avoid an undue large
weight for studies with low or high prevalence (prevalence close to 0 or 1),
we used the Freeman-Tukey arcsine methodology [14]. Publication bias was
assessed by Egger’s test [15]. Statistical heterogeneity was assessed using
the between-study variance s2 estimation [16], and subgroup and sensitivity
analysis were used to account for possible sources of heterogeneity. For time
trends, the estimated coefﬁcients were retransformed to prevalence and
ﬁtted values were drawn against the index year [17]. Statistical analysis was
performed by use of Stata v13 software package (Stata Corporation, College
Station, TX). The signiﬁcance threshold was set at .05.
RESULTS
Our initial literature search yielded 74,214 citations and
the date of our last access to the databases was March 28,
2014. After scrutinizing the title and abstract of the retrieved
citations, 132 articles were assessed in full text and 83 of
these studies were excluded because they did not provide
extractable data on the prevalence of CDI among HSCT
patients. The remaining 49 studies were considered suitable
for our analysis (Supplementary Appendix). Six studies
contained partially overlapping data, and therefore the
maximum of relevant information was extracted from each.
Details for the selection process of eligible articles are pre-
sented in the ﬂow chart (Supplementary Appendix).
The 48 included studies (coded from 49 articles) were
published from 1982 to 2014 and reported data on 12,025
HSCT patients from 1980 to 2012. Data from the individual
studies are presented in Supplementary Table S2. On the
basis of the Newcastle-Ottawa scale, all studies were deemed
of adequate quality to be included in the analysis(Supplementary Table S3). Twelve studies were prospective
and 34 were retrospective, whereas 1 study contained both
prospectively and retrospectively collected data and 1 did
not report the study design. Among 48 included studies, 30
studies were conducted in North America, 12 in Europe, 4 in
Asia, 1 in Australia, and 1 in South America.
The pooled prevalence of CDI among 12,025 HSCT pa-
tients from 48 studies was 7.9% (95% CI, 6.5% to 9.5%), an
estimation that was relatively consistent among studies
(s2 ¼ .032). Across the 30 studies conducted in North
America, the estimated prevalence of CDI was 8.4% (95% CI,
6.8% to 10.2%), which was higher than, but not signiﬁcantly
different from the estimated prevalence among European
studies (6.0% [95% CI, 2.8% to 10.3%], P ¼ .20). There was no
evidence of publication bias, according to the Egger’s test
both for the overall estimate as well as the estimate across
studies conducted in North America (bias .24, P ¼ .81;
bias .15, P ¼ .88, respectively). We also made a subgroup
analysis based on the study design (prospective versus
retrospective) and found that this factor did not alter
signiﬁcantly the estimated prevalence of CDI among HSCT
patients (P ¼ .86). Moreover, we stratiﬁed studies based on
the duration of follow-up, namely follow-up during hospi-
talization or less than dayþ100 versus follow-up longer than
day þ100, and we did not ﬁnd a signiﬁcant difference in the
reported prevalence of CDI (P ¼ .94) (Table 1).
The index year of all eligible articles was used to study the
trend of CDI over time. An increasing trend was observed
over the years among all studies (P ¼ .02) (Figure 1A) and
among the studies that were conducted exclusively in North
America (P ¼ .03) (Figure 1B). Of note is that 2 studies
(reporting data on 130 patients) did not report the time
frame of the study and, therefore, they were not included in
the modeling of CDI over time.
Twenty-four studies provided extractable data on 4665
autologous HSCT patients, whereas 24 studies reported
relevant data on 5120 allogeneic HSCT patients. The preva-
lence of CDI among patients undergoing allogeneic
transplantation was 9.3% (95% CI, 7.0% to 11.9%), which was
signiﬁcantly higher than the corresponding ﬁgure among
autologous transplant recipients (5.2% [95% CI, 3.8% to 6.9%],
P ¼ .02). Among the 6 studies with 200 patients that
reported stratiﬁed data on both autologous and allogeneic
transplant recipients, the point estimate of CDI prevalence
continued to be higher among allogeneic HSCT patients, but
the estimated difference was not statistically signiﬁcant
(12.9% [95% CI, 6.9% to 20.4%] versus 7.1% [95% CI, 5.6% to
8.8%], respectively [P ¼ .11]).
Thirteen studies provided data on episodes of recurrence
among a total of 480 infected patients. Individual study data
are presented in Supplementary Table S2. The reported
recurrence rate across studies spanning the last decade
ranged from 0 to 27%. However, as discussed below, the
quality of data did not allow further analysis.
Six studies reported data regarding the severity of CDI
among infected patients. Two studies did not report any
severe cases of CDI among 16 and 53 infected patients and
another 2 studies reported 1 episode of death each due to
colitis out of 6 and 8 infected patients. Finally, 2 studies
reported 1 severe CDI each that required intensive care unit
admission (of 51 and 72 infected patients). Also, only 2
studies (both from Europe), which were published in 2012
and 2014, evaluated the prevalence of BI/NAP1/027 strain
among the infected patients and neither of these studies
Table 1
Summary Estimates
C. Difﬁcile Infections Studies (arms) N Combined Effect (95% CI) s2 P Value
All studies 48 (49) 12,025 7.9% (6.5%-9.5%) .032
Studies 200 patients 22 9628 6.6% (4.9%-8.5%) .026 Ref.
Studies <200 patients 27 2397 9.7% (7.0%-12.8%) .055 .08
Geographic region
North America 30 (31) 9160 8.4% (6.8%-10.2%) .024 Ref.
Europe 12 2186 6.0% (2.8%-10.3%) .068 .20
Graft type 40 (49)
Autologous 24 4665 5.2% (3.8%-6.9%) .021 Ref.
Allogeneic 24 5120 9.3% (7.0%-11.9%) .035 .02
Duration of follow-up
During initial hospitalization 36 8505 7.3% (5.2%-9.7%) .062 Ref.
Further follow-up 14 3856 7.1% (4.6%-10.1%) .034 .94
Study design
Prospective 13 1587 8.2% (4.9%-12.4%) .049 Ref.
Retrospective 35 10,388 7.8% (6.2%-9.5%) .030 .86
Ref indicates referent subgroup for comparison.
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population. Finally, no study examined the impact of CDI on
the length of hospital stay.
DISCUSSION
Hematopoietic transplant recipients are particularly
vulnerable to C. difﬁcile infection and an increasing numberFigure 1. Prevalence of CDI over time. (A) Observed (triangles) and ﬁtted (line)
CDI prevalence estimates (all studies), by study midyear. (B) Observed (tri-
angles) and ﬁtted (line) CDI prevalence estimates, by study midyear, for
studies conducted in North America.of retrospective and prospective studies are published to
address this association [8]. Indeed, we found an overall
prevalence of CDI of 7.9%, which is circa 9 times higher than
what is reported in the general hospital population (.9% of all
hospital stays in 2009) [3]. Importantly, we observed that
hematopoietic transplant recipients are being increasingly
diagnosed with CDI over the last 34 years. This trend
remained signiﬁcant when studies conducted exclusively in
North America were examined and can reﬂect an actual
change in C. difﬁcile epidemiology because of the emergence
of more virulent strains [5,18].
In our analysis, we observed that approximately 1 of 10
allogeneic transplant recipients is diagnosed with CDI during
the peri-transplantation and late post-transplantation
periods, compared with 1 of 20 autologous transplant
recipients, and this difference was statistically signiﬁcant.
Indeed, allogeneic transplant recipients are more prone to CDI
than autologous HSCT patients and this difference has been
attributed to the higher degree of immunosuppression,
increased exposure to antibiotics, and disruption of bowel
microbial ecology by GVHD [19,20]. However, the risk of
developing C. difﬁcile infection can be affected by several
factors, such as regional epidemiology, time trends, and the
use of different antimicrobial regimens for prophylaxis and
treatment. To overcome these confounding factors, we sepa-
rately analyzed large studies (over 200 patients) that provided
stratiﬁed data on allogeneic and autologous transplantation
patients. Again, allogeneic patients were more likely to be
diagnosed with CDI, even though the difference in this com-
parison did not reach statistical signiﬁcance (P¼ .11). Of note is
that allogeneic transplant recipients may be more frequently
investigated for diarrheal symptoms, and, therefore, there
might be an increased possibility of identifying asymptomatic
C. difﬁcile colonization among this population [20].
The studies included in our meta-analysis had different
follow-up protocols that ranged from 3 weeks to 2 years.
Although, it is reasonable to assume that a longer the dura-
tion of follow-up is associated with a higher the number of
identiﬁed CDIs, we did not ﬁnd a signiﬁcant difference in CDI
prevalence between studies that followed patients only over
the peri-transplantation period, compared with those that
followed patients through the late post-transplantation
period. This can be interpreted as an indication that the
majority of CDIs occur in the peri-transplantation period
(<100 days). That is reasonable, if we acknowledge that
during this period patients are hospitalized for a prolonged
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spectrum antibiotics, and (relevant for allogeneic HSCT
patients) suffer the effects of acute GVHD, which alters the
normal colonizing gastrointestinal ﬂora.
Of note is that newer diagnostic methods have been
shown in prospective studies to be more sensitive in
detecting toxins of C. difﬁcile [21]. Therefore, the observed
increasing trend of CDI might be, at least in part, the result of
the increased sensitivity of molecular methods that are now
more frequently used. We could not account for such a
difference, as some of the available studies did not provide
the exact method for detecting the toxin in stool, whereas
others used more than 1 diagnostic method over the study
period, without reporting stratiﬁed data on the prevalence of
infections.
Recurrence is a common and challenging problem among
C. difﬁcileeinfected patients and multiple studies have
identiﬁed factors that can predict rate of recurrence [22,23].
The age of the patient, comorbid conditions, severity of the
initial episode, and antibiotic used for its treatment, as well
as re-exposure to antibiotics after successful treatment of the
initial episode, are thought to be independent factors that
can predict recurrence [24,25]. The recurrence rate reported
in studies published over the last 10 years and included in
our analysis varied from 0% to 27% (Supplementary Table S2).
However, as the recurrence rate was a secondary outcome in
all included studies, there was no concrete follow-up period
after the initial episode and, thus, individual study data could
not be pooled. Studies following C. difﬁcileeinfected HSCT
patients for a concrete period of time are needed to specify
the recurrence rate in this population, which has speciﬁc
characteristics (younger age, increased exposure to antibi-
otics, immunosuppression) and to specify whether recurrent
episodes are relapses of CDI or reinfections.
Meta-analyses are inherently subject to publication bias.
To minimize this possibility, we included in our analysis both
published studies as well as abstracts from conference pro-
ceedings published in EMBASE, and we used a broad search
term to identify studies whose primary focus was not the
prevalence of CDI, but the prevalence of other infections as
well. Also, we performed the Egger’s test, which yielded no
evidence of publication bias. Moreover, we did not have
enough data to draw valid conclusions regarding the impact
of CDI in the outcome and length of hospital stay. Finally,
prospective studies are more likely to be conducted in
centers with a high prevalence of CDI and researchers might
be prone to investigate episodes of diarrhea more thor-
oughly, compared with retrospective studies where data are
collected from medical records. However, our estimated
prevalence did not differ signiﬁcantly between prospective
and retrospective studies (P ¼ .86).
CONCLUSION
HSCT patients constitute a highly vulnerable population
for CDI, as our estimated prevalence of 7.9% is almost 9 times
higher than the corresponding estimations for the general
hospital population [3]. Moreover, our data do not support
that the CDI has reached a plateau in this patient population
and our ﬁnding that 1 of 10 allogeneic and 1 of 20 auto-
logous transplant recipients are expected to be diagnosed
with CDI during the peri-transplantation and late post-
transplantation period highlight the need for prevention
policies that apply to the speciﬁc characteristics of this
population. It should be noted that information regarding the
role of NAP-1 strain in this patient population, the severityand outcome of CDI, the rate of recurrence, and the impact of
the infection in the length of hospital stay are not available
from this study. Further, the impact of different diagnostic
tests in the prevalence of CDI could not be determined, as no
pertinent data could be extrapolated from the individual
studies. Future studies should estimate the prevalence of the
Nap1/BI/027 strain in this population and evaluate the
impact of CDI among HSCT patients, and they should include
monitoring for relapse and reinfection.
ACKNOWLEDGMENTS
Financial disclosure: All authors have no ﬁnancial re-
lationships relevant to this article to disclose.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
SUPPLEMENTARY DATA
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.bbmt.2014.06.001.
REFERENCES
1. Kelly CP, LaMont JT. Clostridium difﬁcileemore difﬁcult than ever.
N Engl J Med. 2008;359:1932-1940.
2. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA
infections, 2005-2008. JAMA. 2010;304:641-648.
3. Lucado J, Gould C, Elixhauser A. Clostridium difﬁcile infections (CDI) in
hospital stays, 2009: Statistical Brief #124. Healthcare Cost and Utili-
zation Project (HCUP) Statistical Briefs. Rockville (MD) 2006. Available
at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.jsp.
4. McDonald LC, Owings M, Jernigan DB. Clostridium difﬁcile infection in
patients discharged from US short-stay hospitals, 1996-2003. Emerg
Infect Dis. 2006;12:409-415.
5. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-
institutional outbreak of Clostridium difﬁcile-associated diarrhea with
high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
6. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated
infections: a meta-analysis of costs and ﬁnancial impact on the US
health care system. JAMA Intern Med. 2013;173:2039-2046.
7. CDC. Antibiotic resistance threats in the United States, 2013. Avail-
able at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/
ar-threats-2013-508.pdf.
8. Alonso CD, Marr KA. Clostridium difﬁcile infection among hematopoi-
etic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis.
2013;26:326-331.
9. Willems L, Porcher R, LafaurieM, et al. Clostridiumdifﬁcile infection after
allogeneic hematopoietic stem cell transplantation: incidence, risk fac-
tors, and outcome. Biol Blood Marrow Transplant. 2012;18:1295-1301.
10. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational
studies in epidemiology: a proposal for reporting. Meta-analysis Of
Observational Studies inEpidemiology (MOOSE) group. JAMA. 2000;283:
2008-2012.
11. Kaltsas A, Simon M, Unruh LH, et al. Clinical and laboratory charac-
teristics of Clostridium difﬁcile infection in patients with discordant
diagnostic test results. J Clin Microbiol. 2012;50:1303-1307.
12. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in meta-analyses.
Available at: http://www.ohri.ca/programs/clinical_epidemiology/
oxford.asp.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials. 1986;7:177-188.
14. Fazel S, Khosla V, Doll H, Geddes J. The prevalence of mental disorders
among the homeless in western countries: systematic review and
meta-regression analysis. PLoS Med. 2008;5:e225.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315:629-634.
16. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance
on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol.
2008;8:79.
17. Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Meta-analysis of
methicillin-resistant staphylococcus aureus colonization and risk of
infection in dialysis patients. J Am Soc Nephrol. 2014 [Epub ahead of
print].
18. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-
variant strain of Clostridium difﬁcile. N Engl J Med. 2005;353:
2433-2441.
19. Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts
intestinal microbial ecology by inhibiting Paneth cell production of
alpha-defensins. Blood. 2012;120:223-231.
P. Khandelwal et al. / Biol Blood Marrow Transplant 20 (2014) 1641e1665165420. Callejas-Diaz A, Gea-Banacloche JC. Clostridium difﬁcile: deleterious
impact on hematopoietic stem cell transplantation. Curr Hematol Malig
Rep. 2014;9:85-90.
21. Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic
assay on Clostridium difﬁcile infection and complication rates in a
mandatory reporting program. Clin Infect Dis. 2013;56:67-73.
22. D’Agostino RB Sr, Collins SH, Pencina KM, et al. Risk estimation for
recurrent clostridium difﬁcile infection based on clinical factors. Clin
Infect Dis. 2014;58:1386-1393.Financial disclosure: See Acknowledgments on page 1658.
* Correspondence and reprint requests: Pooja Khandelwal, MD, Division
of Bone Marrow Transplant and Immune Deﬁciency, Cincinnati Children’s
Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229.
E-mail address: Pooja.khandelwal@cchmc.org (P. Khandelwal).
1083-8791/$ e see front matter  2014 American Society for Blood and
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2014.06.03223. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation
of a clinical prediction rule for recurrent Clostridium difﬁcile infection.
Gastroenterology. 2009;136:1206-1214.
24. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difﬁcile-
associated disease: old therapies and new strategies. Lancet Infect Dis.
2005;5:549-557.
25. Hebert C, Du H, Peterson LR, Robicsek A. Electronic health record-based
detection of risk factors for Clostridium difﬁcile infection relapse. Infect
Control Hosp Epidemiol. 2013;34:407-414.Bortezomib for Refractory Autoimmunity in Pediatrics
Pooja Khandelwal 1,*, Stella M. Davies 1, Michael S. Grimley 1,
Michael B. Jordan 1,2, Brian R. Curtis 3, Sonata Jodele 1, Rebecca Marsh 1,
Alexandra J. Filipovich 11Bone Marrow Transplant and Immune Deﬁciency, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
2Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
3 Platelet & Neutrophil Immunology Laboratory, Blood Center of Wisconsin, Milwaukee, WisconsinArticle history:
Received 17 January 2014
Accepted 5 June 2014
Key Words:
Refractory autoimmunity
Autoimmune cytopenias
Bortezomib
Proteasome inhibitiona b s t r a c t
Therapy of refractory autoimmunity remains challenging. In this study, we evaluated the therapeutic effect of
bortezomib, a proteasome inhibitor, by targeting plasma cells in 7 patients (median age, 9.9 years). Four doses
of bortezomib were administered at a dose of 1.3 mg/m2 intravenously (n ¼ 6) or subcutaneously (n ¼ 1)
every 72 hours. Bortezomib was administered at a median of 120 days from laboratory conﬁrmation of au-
toantibodies. All patients had failed 2 or more standard therapies. Rituximab was administered on the ﬁrst
day if B cells were present, and all patients received plasmapheresis 2 hours before bortezomib adminis-
tration. Six patients experienced resolution of cytopenias. Two of 6 patients experienced recurrence of
cytopenias after initial response. Adverse effects include nausea (n ¼ 1), thrombocytopenia (n ¼ 2), Clos-
tridium difﬁcile colitis (n ¼ 1)), febrile neutropenia (n ¼ 1), and cellulitis at the subcutaneous injection site
(n ¼ 1). Our experience suggests that bortezomib may be beneﬁcial in the treatment of refractory autoim-
munity in children.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autoimmune cytopenias occur as isolated events, as
manifestations of various immune deﬁciencies, and are also a
troublesome complication of allogeneic stem cell trans-
plantation [1,2]. Autoimmune cytopenias are associated with
signiﬁcant morbidity, either attributed to the cytopenia
alone or to the immune suppression required for its man-
agement [3,4]. The largest pediatric series of autoimmune
hemolytic anemia after stem cell transplant estimated an
incidence of about 6% and reported a high rate of mortality
(53%) [5].
Current treatment for autoimmune cytopenias includes
high-dose corticosteroids, intravenous immunoglobulin,
rituximab, mycophenolate mofetil, and sirolimus [3]. Despite
the availability of multiple therapeutic modalities, autoim-
mune cytopenias can be refractory to such treatments [3].
Aberrant production of autoantibodies by self-reactive
plasma cells is an inherent characteristic of autoimmunediseases [6]. Findings show that long-lived plasma cells,
refractory to immunosuppressant and B celledepletion ther-
apies, contribute to themaintenance of humoralmemory and,
in autoimmunity, to autoreactive memory [7]. Long-lived
plasma cells can sustain chronic inﬂammatory processes in
autoimmune diseases by continuously secreting pathogenic
antibodies [6,7]. Proteasome inhibitors target plasma cells
and effectively deplete this antibody-producing compartment
[8]. Bortezomib has been used in refractory autoimmune
diseases in adults and various case reports document suc-
cessful treatments [9]. In addition, a case report of a patient
with systemic lupus erythematosus and multiple myeloma
describes the resolution of both disorders when treated with
proteasome inhibition [10]. Reports have documented the
success of bortezomib in treatment of anti-HLA antibodies
and treatment of refractory acute cellular rejection in patients
after a solid organ transplant [11-14]. In patients with
antibody-mediated rejection after renal transplantation,
bortezomib has successfully reversed the histologic changes
and induced a reduction in donor speciﬁc anti-HLA antibody
levels [15-17]. These reports have also demonstrated that
bortezomib achieves this by depleting HLA-speciﬁc antibody
producing plasma cells [18-20].
We hypothesize that autoimmune cytopenias become
refractory because current therapies do not target autor-
eactive plasma cells, and outcomes can be improved with
plasma cell agents. In this report we describe 7 children and
